The reiteration of the 'Sector Perform' rating and maintenance of the $12 price target by RBC Capital suggests a neutral outlook on Bausch Health Companies' stock in the short term. This analysis is based on the current market perception and the analyst's view, which does not indicate a significant change in the company's valuation or market position. Therefore, the impact on the stock price is likely to be neutral, reflecting the analyst's expectation of the company's performance aligning with the sector's overall performance.